Dual diagnosis treatment for Miami — substance use and mental health, together.

RECO Intensive sits about 50 miles north of Brickell on I-95 — close enough for family involvement, far enough to break the daily routines and social ties that keep Miami clients cycling through relapse. Dual diagnosis is treated by one coordinated team: in-house addiction psychiatry, trauma-trained therapists, and ASAM-based level-of-care decisions. For clients whose depression, anxiety, PTSD, or bipolar disorder has been driving the substance use, that integration is the clinical difference.

For families in Brickell, Coral Gables, Coconut Grove, Aventura, or Pinecrest looking at residential or day-treatment options for a loved one with both addiction and a psychiatric diagnosis, the drive north to RECO Intensive in Delray Beach runs roughly 50 miles up I-95 — about 65 minutes in light traffic, longer at rush hour. That distance is the point. Most Miami clients who choose RECO pair clinical programming with on-site sober living rather than commuting daily, because separating the work of early recovery from the social circles, neighborhoods, and dealers tied to active use is itself a clinical intervention. South Florida’s recovery infrastructure is concentrated in Palm Beach County for a reason: the geography supports the treatment.

Dual diagnosis treatment at RECO means integrated care for substance use disorder and a co-occurring psychiatric condition — major depression, generalized anxiety, PTSD, bipolar disorder, ADHD — delivered by the same clinical team in the same building. Not sequential. Not siloed. The therapist who runs your trauma processing session knows what the psychiatrist adjusted on your mood stabilizer that morning, and the psychiatrist knows what came up in group last week. That coordination is unglamorous, but it is the mechanism by which dual diagnosis treatment actually works.

Why integrated treatment outperforms sequential

For decades, the standard approach was to “get clean first, then deal with the mental health stuff” — or vice versa. The outcomes data on that model is poor. SAMHSA and the bulk of peer-reviewed research over the last twenty years point to the same conclusion: integrated treatment, where both conditions are addressed simultaneously by a single coordinated team, produces meaningfully better retention, lower relapse rates, and better functional outcomes than treating one diagnosis and then the other.

The mechanism is intuitive. When someone with untreated PTSD is told to stop drinking, the alcohol comes off and the nightmares, hypervigilance, and dissociation come back online — often more intensely than before. Without trauma treatment running in parallel, the relapse risk is enormous. The same is true of untreated depression in someone leaving stimulants, or untreated anxiety in someone tapering off benzodiazepines. The “untreated” diagnosis becomes the engine of the next relapse. Sequential models leave clients to manage that on their own. Integrated treatment doesn’t.

The conditions most commonly co-occurring with substance use disorder

The conditions RECO sees most frequently alongside substance use are major depressive disorder, generalized anxiety disorder, post-traumatic stress disorder, bipolar I and II, and adult ADHD. Each has a defined assessment protocol on intake — structured clinical interviews, standardized screeners like the PHQ-9, GAD-7, PCL-5, and MDQ — and each has an evidence-based treatment pathway built into the program.

• Depression: CBT and behavioral activation in individual therapy; SSRIs or SNRIs when clinically indicated; careful attention to differentiating substance-induced mood symptoms from primary depression, which usually requires 30+ days of sobriety to assess accurately.
• Anxiety disorders: CBT with exposure components, DBT skills for distress tolerance, and non-habit-forming pharmacotherapy — buspirone, SSRIs, hydroxyzine — rather than benzodiazepines in active recovery.
• PTSD: EMDR and Trauma-Focused CBT as primary modalities, with prazosin for nightmares and SSRIs as adjuncts.
• Bipolar disorder: Mood stabilizers (lithium, lamotrigine, valproate) managed by the in-house psychiatrist, with psychoeducation around how alcohol and stimulants destabilize mood cycling.
• ADHD: Careful, structured assessment after a period of abstinence; non-stimulant options (atomoxetine, bupropion) considered first in clients with stimulant use histories.

Trauma-focused therapy as a core modality

A substantial share of substance use disorder is downstream of unprocessed trauma — childhood adverse experiences, sexual assault, combat exposure, medical trauma, the cumulative weight of complex relational trauma. Treating the substance use without addressing the trauma history that drives it tends to produce short-term abstinence followed by relapse, because the underlying nervous-system dysregulation is still there.

RECO’s clinical team is trained in Trauma-Focused CBT, EMDR (Eye Movement Desensitization and Reprocessing), and trauma-informed group facilitation. Trauma work isn’t bolted on at the end of treatment; it’s integrated into the weekly schedule for clients who screen positive for trauma histories on the PCL-5 or in clinical interview. That work happens at the PHP level of care and continues through intensive outpatient, with pacing adjusted to each client’s window of tolerance.

In-house psychiatry coordinated with therapy

One of the structural problems with outpatient dual diagnosis treatment in most markets is fragmentation. A client sees a therapist at one office, a psychiatrist at another, and the two providers may exchange a fax once a quarter if at all. Medication decisions happen in isolation from what’s surfacing in therapy. Therapeutic interventions happen without the prescriber knowing.

RECO’s model puts the prescribing psychiatrist and the primary therapist in the same building, often consulting in person. If a client’s anxiety spikes during trauma processing, the therapist can walk down the hall. If the psychiatrist adjusts a mood stabilizer, the therapist knows before the next session. For clients with opioid use disorder, that same coordination governs MAT decisions — naltrexone, Vivitrol injections, or buprenorphine — alongside the psychiatric medication regimen. For alcohol use disorder, naltrexone and acamprosate are managed the same way. Detailed clinical pathways for those conditions are covered in the alcohol treatment and opioid treatment overviews.

Levels of care, length of stay, and what comes after

RECO uses ASAM criteria — the six-dimensional assessment standard — to determine level of care at intake and at every transition. Most dual diagnosis clients from Miami begin at residential or PHP, step down to IOP as stability builds, and continue with weekly outpatient therapy through the alumni and aftercare program. The full continuum, including structured sober-living housing on the Delray campus, is built specifically for clients who benefit from staying out of their home environment during the early months.

Most major commercial insurance plans — Aetna, Cigna, BCBS, United, Beacon — cover dual diagnosis treatment at RECO. Verification takes about fifteen minutes; details are on the insurance page, or call (866) 396-2008 and the admissions team will run benefits while you’re on the phone.

Serving residents of: Brickell, Coral Gables, Coconut Grove, Aventura, Pinecrest.